News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
405,431 Results
Type
Article (21591)
Company Profile (135)
Press Release (383705)
Section
Business (126158)
Career Advice (976)
Deals (23784)
Drug Delivery (98)
Drug Development (58196)
Employer Resources (89)
FDA (11710)
Job Trends (9353)
News (223648)
Policy (20767)
Tag
Academia (939)
Alliances (31459)
Alzheimer's disease (780)
Approvals (11691)
Artificial intelligence (136)
Bankruptcy (223)
Best Places to Work (7050)
Breast cancer (134)
Cancer (1125)
Cardiovascular disease (93)
Career advice (795)
Cell therapy (184)
Clinical research (48218)
Collaboration (452)
Compensation (167)
COVID-19 (1401)
C-suite (116)
Data (1150)
Diabetes (151)
Diagnostics (3088)
Drug pricing (105)
Earnings (51308)
Events (58661)
Executive appointments (409)
FDA (12358)
Funding (321)
Gene therapy (143)
GLP-1 (557)
Government (2126)
Healthcare (8534)
Infectious disease (1483)
Inflammatory bowel disease (92)
Interviews (134)
IPO (10363)
Job creations (2630)
Job search strategy (714)
Layoffs (284)
Legal (4748)
Lung cancer (168)
Manufacturing (182)
Medical device (5788)
Medtech (5791)
Mergers & acquisitions (13712)
Metabolic disorders (461)
Neuroscience (1078)
NextGen: Class of 2025 (3079)
Non-profit (1158)
Northern California (1240)
Obesity (276)
Opinion (186)
Parkinson's disease (91)
Patents (137)
People (37080)
Phase I (15001)
Phase II (20754)
Phase III (16352)
Pipeline (565)
Policy (89)
Postmarket research (1746)
Preclinical (5443)
Radiopharmaceuticals (171)
Rare diseases (242)
Real estate (3499)
Regulatory (15048)
Research institute (984)
Resumes & cover letters (153)
Southern California (1186)
Startups (2181)
United States (11705)
Vaccines (310)
Weight loss (219)
Date
Last 7 days (407)
Last 30 days (1652)
Last 365 days (22874)
2025 (2988)
2024 (23324)
2023 (25954)
2022 (32892)
2021 (33796)
2020 (31609)
2019 (24804)
2018 (19242)
2017 (21194)
2016 (19384)
2015 (23066)
2014 (17814)
2013 (14646)
2012 (15719)
2011 (16143)
2010 (14855)
Location
Africa (446)
Asia (26853)
Australia (3683)
California (2933)
Canada (1072)
China (258)
Colorado (148)
Connecticut (135)
Europe (56513)
Florida (472)
Georgia (92)
Illinois (270)
Indiana (191)
Japan (100)
Maryland (465)
Massachusetts (2281)
Michigan (86)
Minnesota (180)
New Jersey (992)
New York (909)
North Carolina (565)
Northern California (1240)
Ohio (111)
Pennsylvania (704)
South America (652)
Southern California (1186)
Texas (458)
Utah (100)
Washington State (283)
405,431 Results for "solasia pharma k k".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Lilly Drops Up to $2.5B for Scorpion’s PI3K-inhibitor Molecule
The multi-billion deal, in which Eli Lilly will acquire Scorpion Therapeutics’ STX-478 program, is a shot in the arm for PI3K treatments, which have had a mixed history over the past few years.
January 13, 2025
·
2 min read
·
Dan Samorodnitsky
Press Releases
Ibex Medical Analytics Receives First FDA 510(k) Clearance
February 10, 2025
·
4 min read
Approvals
Roche Wins First-Line Breast Cancer Nod for Oral PI3K Blocker, Projects $2.3B in Peak Sales
With the regulatory approval for advanced breast cancer, Roche’s inavolisib is a potential challenger to Novartis’ PI3K inhibitor Piqray, which last year generated $505 million in revenue.
October 11, 2024
·
2 min read
·
Tristan Manalac
Press Releases
ARS Pharmaceuticals Launches neffyinSchools Program Providing Free Life-Saving Needle-Free Epinephrine For Emergency Use to Eligible K-12 Schools
January 21, 2025
·
10 min read
BioMidwest
Cyrus K. Mirsaidi Named Global CEO to Bridgewest Perth Pharma
Bridgewest Perth Pharma announced that Cyrus K. Mirsaidi is taking the worldwide helm as CEO, including its pharmaceutical supplier division, LumaCina, and its Contract Development and Manufacturing Organization division, NovaCina.
October 24, 2023
·
3 min read
Press Releases
Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC
January 30, 2025
·
5 min read
Pharm Country
Glenmark Pharmaceuticals Inc., USA Issues Voluntary Nationwide Recall for Potassium Chloride Extended-Release Capsules, USP (750 mg) 10 mEq K Due To Failed Dissolution
Glenmark Pharmaceuticals Inc. is voluntarily recalling 114 batches of Potassium Chloride Extended-Release Capsules, USP 10 mEq K, to the consumer level.
June 25, 2024
·
13 min read
Pharm Country
Intelligent Bio Solutions Completes In-Clinic Portion of Pharmacokinetic (PK) Study Part of 510(k) Pathway for Approval & Commences Review of Results
Intelligent Bio Solutions Inc. today announced the successful completion of the in-clinic portion of its pharmacokinetic (PK) study, a core component of the Company’s clinical study plan for its 510(k) pathway for regulatory approval.
June 28, 2024
·
4 min read
Solasia Announces Launch of Darvias® in Japan
Solasia Pharma K.K. officially announced that an organoarsenic drug “DARVIAS® Injection 135mg” has been launched today in Japan for use in relapsed or refractory Peripheral T-Cell Lymphoma.
August 22, 2022
·
1 min read
Business
FSD Pharma provides Corporate Update
FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions is pleased to provide the following corporate update.
June 28, 2024
·
10 min read
1 of 40,544
Next
